BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22133146)

  • 1. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL.
    Leong S; McKay MJ; Christopherson RI; Baxter RC
    J Proteome Res; 2012 Feb; 11(2):1240-50. PubMed ID: 22133146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis.
    Lai TC; Chou HC; Chen YW; Lee TR; Chan HT; Shen HH; Lee WT; Lin ST; Lu YC; Wu CL; Chan HL
    J Proteome Res; 2010 Mar; 9(3):1302-22. PubMed ID: 20052998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.
    Leong S; Nunez AC; Lin MZ; Crossett B; Christopherson RI; Baxter RC
    J Proteome Res; 2012 Jul; 11(7):3561-72. PubMed ID: 22587632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.
    Xu J; Zhou JY; Tainsky MA; Wu GS
    Cancer Res; 2007 Feb; 67(3):1203-11. PubMed ID: 17283156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteome changes induced by overexpression of the p75 neurotrophin receptor (p75NTR) in breast cancer cells.
    Wilmet JP; Tastet C; Desruelles E; Ziental-Gelus N; Blanckaert V; Hondermarck H; Le Bourhis X
    Int J Dev Biol; 2011; 55(7-9):801-9. PubMed ID: 22161836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis.
    Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A
    Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy.
    Xu J; Zhou JY; Wu GS
    Cancer Res; 2006 Oct; 66(20):10092-9. PubMed ID: 17047073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic analysis of infiltrating ductal carcinoma tissues by coupled 2-D DIGE/MS/MS analysis.
    Davalieva K; Kiprijanovska S; Broussard C; Petrusevska G; Efremov GD
    Mol Biol (Mosk); 2012; 46(3):469-80. PubMed ID: 22888636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
    Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
    Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.